This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity: A 16-Week Randomized, Double-Blind, Placebo-Controlled Trial

Grigori Joffe, MD, PhD; Pirjo Takala, MD; Evgueni Tchoukhine, MD; Helinä Hakko, PhD; Mirjam Raidma, MD; Hanna Putkonen, MD, PhD; Markku Eronen, MD, PhD; and Pirkko Räsänen, MD, PhD

Published: May 11, 2008

Article Abstract

Objective: Undesirable metabolic effects of modern antipsychotics, especially clozapine and olanzapine, merit development of new weight-control strategies, including pharmacologic ones. We investigated the feasibility of treatment with orlistat, a weight-control drug with no central effects, for overweight/obesity in clozapine- or olanzapine-treated male and female patients.

Method: Add-on orlistat was prescribed for 16 weeks in a randomized, double-blind, placebo-controlled clinical trial to patients who were receiving stable clozapine or olanzapine medication and were aged 18 to 65 years, with no compliance with nonpharmacologic programs or hypocaloric diet required. The primary efficacy variable was body weight change. The study was conducted from 2004 through 2005.

Results: Of 71 randomly assigned subjects, 63 were eligible for modified intent-to-treat analysis. While no statistically significant effect was observed in the whole population, male (but not female) patients benefited from treatment with orlistat (-2.36 kg vs. 0.62 kg on placebo, p = .011). There were 5 responders (16.1%) (those with >= 5% weight loss) that received orlistat versus 2 responders (6.3%) that received placebo (number needed to treat = 11), but the difference was not statistically significant.

Conclusions: Without a hypocaloric diet, the effect of orlistat in overweight/obese clozapine- or olanzapine-treated patients is modest and may only be seen in men. More studies should define the optimal length of treatment and feasibility of combination of orlistat with behavioral programs in this population.

Trial Registration: Identifier: ISRCTN65731856′ ‹

Volume: 69

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF